New Research Demonstrates the Clinical Utility with Daxor’s Blood Volume Analyzer (BVA-100®) in Critical Care
February 04 2021 - 8:30AM
Daxor Corporation
(NYSE MKT: DXR) the global
leader in blood volume measurement technology, today announces new
data from the University of Hawaii John A. Burns School of Medicine
showing the BVA-100 blood test accurately and uniquely reflects
blood volume status after massive blood transfusion, a key metric
for this procedure, while traditional clinical metrics fail in 80%
of the cases analyzed.
The aim of the study titled “A Quantitative
Analysis of Clinical End Points of Resuscitation After Massive
Blood Transfusion,” was to perform a comparative analysis of blood
volume status following massive transfusion protocols (MTP), both
clinically and quantitatively, to determine if endpoints of
resuscitation were adequately achieved utilizing the BVA-100 blood
test. Jonathan Feldschuh, Daxor's Chief Scientific Officer stated
"A key goal of MTP is to save critically ill patients suffering
severe blood loss by transfusing them to euvolemia -- when care
teams do not give optimal transfusions there can be significant
negative and sometimes fatal outcomes."
Data presented revealed that only 20% of the
patients in this study were euvolemic (optimal blood volume), with
24% demonstrating hypovolemia (too little blood volume), despite
meeting traditional clinical surrogates indicative of euvolemia.
Whitney Carlton, M.D., lead investigator concluded, “Traditional
endpoints of resuscitation after implementation of MTP may not
accurately reflect true blood volume.”
“This data is concordant with a wide body of
published studies showing that indirect measures offer low clinical
utility as indicators of true intravascular volume status,” said
Michael Feldschuh, President and CEO of Daxor Corporation. “The
BVA-100 blood test provides a simple and accurate means to directly
measure blood volume and composition ensuring that MTP is effective
and accurate. We are excited that our diagnostic is being used to
support the ongoing research in the area of critical care.”
About Daxor Corporation
Daxor Corporation (NYSE: DXR) is the global
leader in blood volume measurement technology focused on blood
volume testing innovation (organized as an investment company with
fully owned innovative medical instrumentation and biotechnology
operations). We developed and market the BVA-100® (Blood Volume
Analyzer), the first diagnostic blood test cleared by the FDA to
provide safe, accurate, objective quantification of blood volume
status and composition compared to patient-specific norms. The BVA
technology enhances hospital performance metrics in a broad range
of surgical and medical conditions, including heart failure and
critical care, by informing treatment strategies, resulting in
significantly improved multiple measures of patient outcomes.
Daxor's mission is to advance healthcare by enabling optimal fluid
management with blood volume analysis. Daxor’s vision is optimal
blood volume for all. For more information, please visit our
website at Daxor.com.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret ShapiroSr.
Managing Partner, CORE IR516-222-2560brets@coreir.com
Daxor (AMEX:DXR)
Historical Stock Chart
From Jul 2024 to Aug 2024
Daxor (AMEX:DXR)
Historical Stock Chart
From Aug 2023 to Aug 2024